Targeted therapies in the treatment of colorectal cancers (Q36108618)

12 August 2017

1 reference

title

Targeted therapies in the treatment of colorectal cancers (English)

1 reference

12 August 2017

Todd Alekshun

1

1 reference

PubMed ID

15855893

12 August 2017

Chris Garrett

series ordinal

2

1 reference

12 August 2017

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

12

1 reference

12 August 2017

105-110

1 reference

12 August 2017

2

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

12 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Targeted therapy of colorectal cancer: clinical experience with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200205

10.1177/107327480501200205

21 January 2018

Identifiers

DOI

0 references

PubMed ID

15855893

1 reference

PubMed ID

15855893